UNASSIGNED: Although @entity1499 ( @entity6822 ) is an effective drug for the treatment of @entity981 ( @entity981 ), the @entity137 remains a significant problem. In this prospective study, fifty-four @entity1 with @entity981 were enrolled. 3   g or 5   g   @entity6822 /m(2) was administered over 24 hours. Serum @entity6822 concentrations were determined in 24, 48, and 96 hours after @entity6822 infusion. Serum @entity1011 concentrations and @entity1011 clearance rate (CCR) were determined before and 24 and 48 hours after @entity6822 infusion. A total of 173 courses of @entity6822 infusion were administered. The serum @entity1011 concentrations did not change much after @entity6822 infusion while the CCR was gradually decreased. @entity6822 clearance status was independently related to CCR decrease, with the risk of 8.07 to develop @entity8 in @entity1 with delayed @entity6822 elimination. Serum @entity1011 concentration, serum @entity1011 ratio, CCR, and CCR ratio at 24 hours were all related to @entity6822 elimination delay. Patients with serum @entity1011 level >35.0    mol/L, @entity1011 ratio >1.129, or CCR <100.0   mL/min were more likely to undergo @entity6822 elimination delay. In conclusion, @entity6822 could induce transient @entity8 and compromised renal function will delay @entity6822 clearance. The serum @entity1011 concentration and the ratio and CCR are useful tools for evaluating @entity6822 elimination status.

@entity1499 Associated @entity8 Is Related to Delayed Elimination of High-Dose XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate']
@entity1499 :: (MESH:D008727,Chemical) :: ['Methotrexate']
